United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - ropinirole hydrochloride - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ropinirole hydrochloride - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - ropinirole hydrochloride - oral tablet - 5mg

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - levodopa 6 [hp_x] in 1 ml - for temporary relief of anxiety, chest congestion with constriction, disorientation, shakiness, hay fever, and hives. for temporary relief of anxiety, chest congestion with constriction, disorientation, shakiness, hay fever, and hives.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - for temporary relief of symptoms such as stiff muscles, tremors, weakness, and fatigue.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms such as stiff muscles, tremors, weakness, and fatigue.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 0.285mg equivalent to to 0.25 mg ropinirole - film coated tablet - 0.25 mg - active: ropinirole hydrochloride 0.285mg equivalent to to 0.25 mg ropinirole excipient: citric acid hyprolose hypromellose lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 0.57mg equivalent to to 0.5 mg ropinirole - film coated tablet - 0.5 mg - active: ropinirole hydrochloride 0.57mg equivalent to to 0.5 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 1.14mg equivalent to to 1 mg ropinirole - film coated tablet - 1 mg - active: ropinirole hydrochloride 1.14mg equivalent to to 1 mg ropinirole excipient: citric acid hyprolose hypromellose indigo carmine aluminium lake iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole - film coated tablet - 2 mg - active: ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide red lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 3.42mg equivalent to to 3 mg ropinirole - film coated tablet - 3 mg - active: ropinirole hydrochloride 3.42mg equivalent to to 3 mg ropinirole excipient: citric acid cochineal hyprolose hypromellose indigo carmine aluminium lake lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.